MorphoSys plans to reveal the target molecule of its lead antibody program MOR103 and additional information on the design of the Phase I clinical study on January 16, 2008.
Marlies Sproll, chief scientific officer of MorphoSys, said: “The initiation of clinical development of our lead proprietary drug candidate MOR103 is a significant milestone for MorphoSys and we achieved it as planned by the end of 2007.”